# A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

> **NCT02041260** · PHASE2 · UNKNOWN · sponsor: **Thomas Jefferson University** · enrollment: 43 (actual)

## Conditions studied

- Differentiated Thyroid Cancer (DTC)
- Poorly Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT02041260
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2022-05
- **Final completion:** 2022-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02041260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02041260, "A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02041260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*